The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence: indications for adjuvant therapy: an analysis of the Kinki GIST registry

1. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM,

Brennan MF. Two hundred gastrointestinal stromal tumors:

recurrence patterns and prognostic factors for survival. Ann Surg.

2000;231:51–8.

2. Steigen SE, Eide TJ. Trends in incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population

of northern Norway. APMIS. 2006;114:192–200.

3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol.

2006;23:70–83.

4. Teranishi R, Takahashi T, Nishida T, Kurokawa Y, Nakajima

K, Koh M, et al. Plasma trough concentration of imatinib and

13

5. 6. 7. 8. 9. 10. 11. 12. 13. 14. 15. 16. 17. 18. R. Teranishi et al.

its effect on therapeutic efficacy and adverse events in Japanese

patients with GIST. Int J Clin Oncol. 2023;28:680–7.

Teranishi R, Takahashi T, Nishida T, Hirota S, Kurokawa Y, Saito

T, et al. Efficacy and safety of regorafenib in Japanese patients

with advanced gastrointestinal stromal tumors. Int J Clin Oncol.

2022;27:1164–72.

Cavnar MJ, Seier K, Curtin C, Balachandran VP, Coit DG, Yoon

SS, et al. Outcome of 1000 patients with gastrointestinal stromal

tumor (GIST) treated by surgery in the pre- and post-imatinib eras.

Ann Surg. 2021;273:128–38.

DeMatteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters

PWT, Demetri GD, et al. Adjuvant imatinib mesylate after

resection of localised, primary gastrointestinal stromal tumour:

a randomised, double-blind, placebo-controlled trial. Lancet.

2009;373:1097–104.

Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, et al. Time to definitive failure to the

first tyrosine kinase inhibitor in localized GI stromal tumors

treated with imatinib as an adjuvant: a European Organisation

for Research and Treatment of Cancer Soft Tissue and Bone

Sarcoma Group Intergroup Randomized Trial in Collaboration

With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group,

and Spanish Group for Research on Sarcomas. J Clin Oncol.

2015;33:4276–83.

Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D,

Schütte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA.

2012;307:1265–72.

Cho H, Nishida T, Takahashi T, Masuzawa T, Hirota S. Impact

of the KIT/PDGFRA genotype on prognosis in imatinib-naïve

Japanese patients with gastrointestinal stromal tumor. Ann Gastroenterol Surg. 2022;6:241–8.

Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, et al. Diagnosis of gastrointestinal stromal tumors: a

consensus approach. Hum Pathol. 2002;33:459–65.

Rutkowski P, Nowecki ZI, Michej W, Debiec-Rychter M,

Woźniak A, Limon J, et al. Risk criteria and prognostic factors

for predicting recurrences after resection of primary gastrointestinal stromal tumor. Ann Surg Oncol. 2007;14:2018–27.

Takahashi T, Nakajima K, Nishitani A, Souma Y, Hirota S,

Sawa Y, et al. An enhanced risk-group stratification system for

more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007;12:369–74.

Yamamoto K, Tsujinaka T, Takahashi T, Sato S, Nishiguchi

Y, Nakashima Y, et al. Impact of the Japanese gastric cancer

screening system on treatment outcomes in gastric gastrointestinal stromal tumor (GIST): an analysis based on the GIST

registry. Ann Surg Oncol. 2015;22:232–9.

Joensuu H. Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol. 2008;39:1411–9.

Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE,

Brabec P, et al. Risk of recurrence of gastrointestinal stromal

tumour after surgery: an analysis of pooled population-based

cohorts. Lancet Oncol. 2012;13(3):265–74.

Nishida T, Hirota S, Yanagisawa A, Sugino Y, Minami M, Yamamura Y, et al. Clinical practice guidelines for gastrointestinal

stromal tumor (GIST) in Japan: English version. Int J Clin Oncol.

2008;13:416–30.

Wada N, Kurokawa Y, Nishida T, Takahashi T, Toyokawa T,

Kusanagi H, et al. Subgroups of patients with very large gastrointestinal stromal tumors with distinct prognoses: a multicenter

study. J Surg Oncol. 2014;109:67–70.

13

19. Sato S, Tsujinaka T, Yamamoto K, Takahashi T, Kishi K, Imamura

H, et al. Primary surgery as a frontline treatment for synchronous

metastatic gastrointestinal stromal tumors: an analysis of the Kinki

GIST registry. Surg Today. 2016;46:1068–75.

20. Sato S, Tsujinaka T, Masuzawa T, Yamamoto K, Takahashi T,

Yamashita Y, et al. Role of metastasectomy for recurrent/metastatic gastrointestinal stromal tumors based on an analysis of the

Kinki GIST registry. Surg Today. 2017;47:58–64.

21. Yasui M, Tsujinaka T, Mori M, Takahashi T, Nakashima Y,

Nishida T. Characteristics and prognosis of rectal gastrointestinal stromal tumors: an analysis of registry data. Surg Today.

2017;47:1188–94.

22. Nishida T, Cho H, Hirota S, Masuzawa T, Chiguchi G, Tsujinaka T. Clinicopathological features and prognosis of primary

GISTs with tumor rupture in the real world. Ann Surg Oncol.

2018;25:1961–9.

23. Rutkowski P, Bylina E, Wozniak A, Nowecki ZI, Osuch C, Matlok M, et al. Validation of the Joensuu risk criteria for primary

resectable gastrointestinal stromal tumour—the impact of tumour

rupture on patient outcomes. Eur J Surg Oncol. 2011;37:890–6.

24. Shimada H. Real-world data related to the topics of 6th edition

of gastric cancer treatment guidelines. Ann Gastroenterol Surg.

2021;5:730.

25. Dematteo RP, Gold JS, Saran L, Gönen M, Liau KH, Maki RG,

et al. Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal

tumor (GIST). Cancer. 2008;112:608–15.

26. Yanagimoto Y, Takahashi T, Muguruma K, Toyokawa T, Kusanagi

H, Omori T, et al. Re-appraisal of risk classifications for primary

gastrointestinal stromal tumors (GISTs) after complete resection:

indications for adjuvant therapy. Gastric Cancer. 2015;18:426–33.

27. Joensuu H, Wardelmann E, Eriksson M, Reichardt A, Sundby

Hall K, Schütte J, et al. KIT and PDGFRA mutations and survival of gastrointestinal stromal tumor patients treated with

adjuvant imatinib in a randomized trial. Clin Cancer Res.

2023;29(17):3313–9.

28. Nishida T, Sato S, Ozaka M, Nakahara Y, Komatsu Y, Kondo M,

et al. Long-term adjuvant therapy for high-risk gastrointestinal

stromal tumors in the real world. Gastric Cancer. 2022;25:956–65.

29. Hølmebakk T, Hompland I, Bjerkehagen B, Stoldt S, Bruland

ØS, Hall KS, et al. Recurrence-free survival after resection of

gastric gastrointestinal stromal tumors classified according to a

strict definition of tumor rupture: a population-based study. Ann

Surg Oncol. 2018;25:1133–9.

30. Bischof DA, Kim Y, Dodson R, Jimenez MC, Behman R, Cocieru

A, et al. Conditional disease-free survival after surgical resection

of gastrointestinal stromal tumors: a multi-institutional analysis

of 502 patients. JAMA Surg. 2015;150:299–306.

31. Kurokawa Y, Yang HK, Cho H, Ryu MH, Masuzawa T, Park SR,

et al. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer. 2017;117:25–32.

32. Wang D, Zhang Q, Blanke CD, Demetri GD, Heinrich MC,

Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib

mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results

of Radiation Therapy Oncology Group 0132. Ann Surg Oncol.

2012;19:1074–80.

33. Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC,

Watson JC, et al. Phase II trial of neoadjuvant/adjuvant imatinib

mesylate (IM) for advanced primary and metastatic/recurrent

operable gastrointestinal stromal tumor (GIST): early results of

RTOG 0132/ACRIN 6665. J Surg Oncol. 2009;99:42–7.

The impact of contour maps on estimating the risk of gastrointestinal stromal tumor recurrence:…

34. Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T,

Kuwano H, et al. 18F-fluorodeoxyglucose positron emission

tomography: useful technique for predicting malignant potential of

gastrointestinal stromal tumors. World J Surg. 2005;29:1429–35.

35. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N,

et al. The role of 18F-FDG PET in staging and early prediction of

response to therapy of recurrent gastrointestinal stromal tumors.

J Nucl Med. 2004;45:17–21.

36. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess

MA, Patel SR, et al. Correlation of computed tomography and

positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib

mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.

37. Van den Abbeele AD. The lessons of GIST-PET and PET/CT: a

new paradigm for imaging. Oncologist. 2008;13(Suppl 2):8–13.

38. Hwang SH, Jung M, Jeong YH, Jo K, Kim S, Wang J, et al. Prognostic value of metabolic tumor volume and total lesion glycolysis

on preoperative (18)F-FDG PET/CT in patients with localized

primary gastrointestinal stromal tumors. Cancer Metab. 2021;9:8.

39. Cho MH, Park CK, Park M, Kim WK, Cho A, Kim H. Clinicopathologic features and molecular characteristics of glucose

metabolism contributing to 18F-fluorodeoxyglucose uptake in

gastrointestinal stromal tumors. PLoS ONE. 2015;10:e0141413.

40. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L,

Harrell P, et al. PDGFRA mutations in gastrointestinal stromal

tumors: frequency, spectrum and in vitro sensitivity to imatinib.

J Clin Oncol. 2005;23:5357–64.

4 1. Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J,

Brown M, et al. Use of c-KIT/PDGFRA mutational analysis to

predict the clinical response to imatinib in patients with advanced

gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J

Cancer (Oxford, England: 1990). 2004;40:689–95.

42. Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren

M, Joensuu H, et al. Kinase mutations and imatinib response in

patients with metastatic gastrointestinal stromal tumor. J Clin

Oncol. 2003;21:4342–9.

Publisher's Note Springer Nature remains neutral with regard to

jurisdictional claims in published maps and institutional affiliations.

13

...